Going-concern and liquidity shortfall
The company stated its cash on hand is insufficient to complete its business plan and that additional financing is required.
- Scope
- Operations and continuity of development programs
- Materiality
- high
Kraig Biocraft Laboratories, Inc.
Kraig Biocraft Laboratories, Inc. develops recombinant spider silk materials using genetically engineered silkworms that produce spider silk proteins. The company is focused on scaling these fibers for technical textiles and other advanced-material applications, while still operating at an early commercial stage with limited revenue and ongoing funding needs.
0.18
0.18
| % | |
|---|---|
| Recombinant spider silk fibers | 70% Genetically engineered silk fibers produced from silkworms for advanced material uses. |
| Technical textile applications | 20% Fiber-based materials intended for performance apparel, workwear, filtration, and composites. |
| Research and development services | 10% Internal and collaborative R&D to improve fiber robustness and develop new materials. |
The company’s target customers are textile, materials, and biotechnology partners that can commercialize spider...
- Textile and apparel partnersprimary
Buy or co-develop spider silk fibers for performance apparel, workwear, and fashion products because of the material's strength and novelty.
- Materials and composites companiessecondary
Use the fibers in flexible composites and other advanced material applications where high strength-to-weight properties matter.
- Biotechnology and research collaboratorssecondary
Work with the company on R&D, product testing, and platform development to expand material capabilities.
- Industrial filtration and specialty end marketsemerging
Potential buyers for spider silk-based materials in filtration and other niche industrial uses.
The company is headquartered in the United States but has emphasized expansion of overseas production operations,...
- •United States headquarters and reporting base
- •Overseas production expansion is a stated operating priority
- •Local contractors and cooperatives support production scale-up
- •Geography matters because manufacturing is tied to specialized silk operations
- •No country-level revenue disclosure was provided in the excerpts
Management is focused on scaling commercial production of recombinant spider silk while improving the robustness of its...
01
Scale commercial productionshort-term
The company needs larger, more reliable output before it can convert technical progress into meaningful sales.
02
Broaden commercialization partnershipsmedium-term
Partnerships can provide manufacturing, marketing, and market access without requiring the company to build everything itself.
03
Secure capital and optionalityshort-term
The company has insufficient cash to execute its plan and must fund operations through debt, equity, or strategic transactions.
Kraig Biocraft is an early-stage development company with substantial going-concern risk because cash resources are...
Financing dilution and restrictive capital terms
The company expects to fund operations through debt or equity, which can dilute shareholders or impose operating restrictions.
- Scope
- Common stock issuance, standby equity facilities, private placements
- Materiality
- high
Commercialization and scale-up failure
The business depends on converting R&D into scalable production and customer adoption, which is unproven at meaningful scale.
- Scope
- Spider silk fibers, textile partnerships, overseas production
- Materiality
- high
Dependence on collaborative partners and contractors
The company plans to use external partners and overseas contractors, which can create quality, timing, and control risks.
- Scope
- Manufacturing and product testing
- Materiality
- medium
Going-concern assessment
May influence valuation, liquidity analysis, and financial statement presentation
Share-based compensation and warrant accounting
Affects operating expenses, equity, and per-share dilution
Fair value measurement of gold bullion
Impacts other income and net loss
Lease accounting
Affects assets, liabilities, and operating cash flow reconciliation
Nkarta, Inc.
NKTX · Pharmaceutical Preparations
Mosaic ImmunoEngineering Inc.
CPMV · Biological Products, (No Diagnostic Substances)
PLIANT THERAPEUTICS, INC.
PLRX · Pharmaceutical Preparations
Pliant Therapeutics is a U.S.-based clinical-stage biopharmaceutical company focused on discovering and developing integrin-based therapeutics.
Cryoport, Inc.
CYRX · Pharmaceutical Preparations
Vir Biotechnology, Inc.
VIR · Biological Products, (No Diagnostic Substances)
Fulgent Genetics, Inc.
FLGT · Services-Medical Laboratories
: 28/04/2026